Related Experiment Videos
Is premenstrual dysphoric disorder a distinct clinical entity?
J Endicott1, J Amsterdam, E Eriksson
1College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
Journal of Women'S Health & Gender-Based Medicine
|June 6, 2000
Summary
Premenstrual dysphoric disorder (PMDD) is a distinct clinical entity, supported by evidence of unique symptoms and treatment responses. Selective serotonin reuptake inhibitors (SSRIs) effectively treat PMDD, validating its status as a separate condition.
Area of Science:
- Psychiatry
- Neuroscience
- Women's Health
Background:
- Premenstrual dysphoric disorder (PMDD) is characterized by severe mood symptoms linked to the menstrual cycle.
- Distinguishing PMDD from other mood and anxiety disorders is crucial for effective treatment.
Purpose of the Study:
- To evaluate the evidence supporting PMDD as a distinct clinical disorder.
- To assess the safety and efficacy of potential PMDD treatments.
Main Methods:
- Expert panel roundtable discussion reviewing available scientific information.
- Contrast of PMDD characteristics with established mood and anxiety disorders.
- Analysis of treatment response data, particularly to serotonergic agents.
Main Results:
- PMDD exhibits a distinct clinical profile with cyclical symptom onset/offset, anger, irritability, and tension.
- Selective serotonin reuptake inhibitors (SSRIs) show high efficacy (≥60% response) at low, sometimes intermittent, doses.
- PMDD features include normal HPA axis function, serotonin system involvement, and a unique genetic component.
Conclusions:
- The expert consensus confirms PMDD as a distinct clinical entity.
- Evidence supports the evaluation of targeted treatments for PMDD.
- Further research can now focus on developing and refining effective PMDD therapies.